Jean-Yves Douillard, MD, PhD, of Centre R Gauducheau, reviews new clinical trials and data on systemic and radiation treatment of small cell lung cancer.
Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.
Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).
Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses the latest developments in an important cancer treatment avenue.
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.
